



Allegato 12

PDTA GIC COLORETTALE – versione 1/2021

COMMITTENTE – Direttore Dipartimento di Rete Oncologica

APPROVAZIONE FINALE – Gruppo di Studio Colorettale / referenti GIC colonretto

ESTENSORI

1) Screening, diagnosi tempestiva, sindromi da predisposizione genetica

Vittoria Grammatico (coordinatore)

Myriam Katja Paris

Francesca Olivero

Marco Naddeo

Elisabetta Fenocchio

Valentina Renda

2) Diagnosi clinica e anatomopatologica e stadiazione pre-trattamento

Annalisa Balbo Mussetto (coordinatore)

Maurizio Spandre

Laura Fanchini

Laura Auriati

Renato Parente

Renzo Clara

Silvia Ramonda

3) Trattamento chirurgico tumori del colon

Roberto Perinotti (coordinatore)

Antonio Masciandaro

Luca Bonatti

Andrea Spinelli

Cravero Francesca

Elisabetta Castagna

Ugo Parisi

Matteo Gatti

4) Trattamento chirurgico tumori del retto

Maria Carmela Giuffrida (coordinatore)

Marcello Zago

Igor Monsellato

Andrea Muratore

Roberto Saracco

Alberto Serventi

Maria Paola Bellomo

Paolo Bellora
Vincenzo Adamo
Francesco Moro

5) Terapia adiuvante e trattamento delle fasi avanzate tumore del colon

Cristiano Oliva (coordinatore)
Franco Sarli
Angelo Giuli
Anna Ferrero
Sara Bustreo

6) Trattamento neoadiuvante, adiuvante e delle fasi avanzate tumore del retto

Cristina Piva (coordinatore)
Elena Traverso
Andrea Galla
Cristina Granetto
Panier Suffat Luca
Roberta Volpatto
Sara Lattuada

7) Follow up e ai problemi riabilitativi

Roberto Rimonda (coordinatore)
Liana Todisco
Davide Ottaviani
Giuliana Ritorto

BIBLIOGRAFIA

Linee guida AIOM 2019

Associazione Italiana di Oncologia Medica. (2019). Linee guida Neoplasie del retto e dell'Ano (Ed 2019 aggiornata a ottobre 2019).

Retrieved from https://www.aiom.it/wpcontent/uploads/2019/10/2019_LG_AIOM_Retto_ano.pdf

Linee guida AIRO 2014

Associazione Italiana di Radioterapia e oncologi clinica. (2014). La radioterapia dei tumori gastrointestinali.

Retrieved from <https://www.radioterapiaitalia.it/wp-content/uploads/2016/08/2014-La-radioterapia-tumori-gastrointest-scaricabile.pdf>

Linee guida ESMO 2017

Glynne-Jones R, Wyrwicz L, Tiret E.

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol 2017;28(suppl_4):iv22–40.

Linee guida NCCN 2020

National Comprehensive Cancer Network. (2020). Rectal Cancer (ver 6.2020).

Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf

Early colorectal cancer

[1] A. Halverson, A. Morris, and R. Cleary, "For Patients with Early Rectal Cancer, Does Local Excision Have an Impact on Recurrence, Survival, and Quality of Life Relative to Radical Resection?," Ann. Surg. Oncol., vol. 26, no. 8, pp. 2497–2506, 2019, doi: 10.1245/s10434-019-07328-5.

- [2] M. Ferlitsch, A. Moss, and C. Hassan, "Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline.," *Endoscopy*, vol. 49, no. 3, pp. 270–297, 2017, doi: 10.1055/s-0043-102569.
- [3] T. McCarty, A. Bazarbashi, and K. Hathorn, "Endoscopic submucosal dissection (ESD) versus transanal endoscopic microsurgery (TEM) for treatment of rectal tumors: a comparative systematic review and meta-analysis.," *Surg. Endosc.*, vol. 34, no. 4, pp. 1688–1695, 2020, doi: 10.1007/s00464-019-06945-1.
- [4] V. Sagae, I. Ribeiro, and D. de Moura, "Endoscopic submucosal dissection versus transanal endoscopic surgery for the treatment of early rectal tumor: a systematic review and meta-analysis.," *Surg. Endosc.*, vol. 34, no. 3, pp. 1025–1034, 2020, doi: 10.1007/s00464-019-07271-2.
- [5] M. Morino, M. Risio, and S. Bach, "Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference.," *Surg. Endosc.*, vol. 29, no. 4, pp. 755–773, 2015, doi: 10.1007/s00464-015-4067-3.
- [6] M. Allaix, A. Arezzo, and M. Morino, "Transanal endoscopic microsurgery for rectal cancer: T1 and beyond? An evidence-based review.," *Surg. Endosc.*, vol. 30, no. 11, pp. 4841–4852, 2016, doi: 10.1007/s00464-016-4818-9.

Presentazione in urgenza

- [1] G. Chang, A. Kaiser, and S. Mills, "Practice parameters for the management of colon cancer.," *Dis. Colon Rectum*, vol. 55, no. 8, pp. 831–843, 2012, doi: 10.1097/DCR.0b013e3182567e13.
- [2] C. van de Velde, P. Boelens, and P. Tanis, "Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012: science, opinions and experiences from the experts of surgery.," *Eur. J. Surg. Oncol.*, vol. 40, no. 4, pp. 454–468, 2014, doi: 10.1016/j.ejso.2013.10.013.
- [3] R. Frago, E. Ramirez, and M. Millan, "Current management of acute malignant large bowel obstruction: a systematic review.," *Am. J. Surg.*, vol. 207, no. 1, pp. 127–138, 2014, doi: 10.1016/j.amjsurg.2013.07.027.
- [4] L. Laine, H. Yang, and S. Chang, "Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009.," *Am. J. Gastroenterol.*, vol. 107, no. 8, pp. 1190–5, 2012, doi: 10.1038/ajg.2012.168.
- [5] A. Barnett, A. Cedar, and F. Siddiqui, "Colorectal cancer emergencies.," *J. Gastrointest. Cancer*, vol. 44, no. 2, pp. 132–142, 2013, doi: 10.1007/s12029-012-9468-0.
- [6] L. Smothers, L. Hynan, and J. Fleming, "Emergency surgery for colon carcinoma.," *Dis. Colon Rectum*, vol. 46, no. 1, pp. 24–30, 2003, doi: 10.1007/s10350-004-6492-6.
- [7] G. Bass, C. Fleming, and J. Conneely, "Emergency first presentation of colorectal cancer predicts significantly poorer outcomes: a review of 356 consecutive Irish patients.," *Dis. Colon Rectum*, vol. 52, no. 4, pp. 678–684, 2009, doi: 10.1007/DCR.0b013e3181a1d8c9.
- [8] N. Runkel, U. Hinz, and T. Lehnert, "Improved outcome after emergency surgery for cancer of the large intestine.," *Br. J. Surg.*, vol. 85, no. 9, pp. 1260–1265, 1998, doi: 10.1046/j.1365-2168.1998.00855.x.
- [9] M. Zielinski, A. Merchea, and S. Heller, "Emergency management of perforated colon cancers: how aggressive should we be?," *J. Gastrointest. Surg.*, vol. 15, no. 12, pp. 2232–2238, 2011, doi:10.1007/s11605-011-1674-8.
- [10] C. Bailey, C. Hu, and Y. You, "Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010.," *JAMA Surg.*, vol. 150, no. 1, pp. 17–22, 2015, doi: 10.1001/jamasurg.2014.1756.
- [11] L. Torre, R. Siegel, and E. Ward, "Global Cancer Incidence and Mortality Rates and Trends--An Update.," *Cancer Epidemiol. Biomarkers Prev.*, vol. 25, no. 1, pp. 16–27, 2016, doi: 10.1158/1055-9965.EPI-15-0578.
- [12] M. Arnold, M. Sierra, and M. Laversanne, "Global patterns and trends in colorectal cancer incidence and mortality.," *Gut*, vol. 66, no. 4, pp. 683–691, 2017, doi: 10.1136/gutjnl-2015-310912.
- [13] L. Ansaloni, R. Andersson, and F. Bazzoli, "Guidelines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society.," *World J. Emerg. Surg.*, vol. 5, p. 29, Dec. 2010, doi: 10.1186/1749-7922-5-29.
- [14] M. Pisano, L. Zorcolo, and C. Merli, "2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation.," *World J. Emerg. Surg.*, vol. 13, p. 36, 2018, doi: 10.1186/s13017-018-0192-3.

Tecnica chirurgica

- [1] N. Battersby, P. How, and B. Moran, "Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study.," *Ann. Surg.*, vol. 263, no. 4, pp. 751–760, 2016, doi: 10.1097/SLA.0000000000001193.
- [2] Y. Hashiguchi, K. Muro, and Y. Saito, "Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.," *Int. J. Clin. Oncol.*, vol. 25, no. 1, pp. 1–42, 2020, doi: 10.1007/s10147-019-01485-z.

- [3] M. Aubert, D. Mege, and Y. Panis, "Total mesorectal excision for low and middle rectal cancer: laparoscopic versus transanal approach-a meta-analysis," *Surg. Endosc.*, vol. 34, no. 9, pp. 3908–3919, 2020, doi: 10.1007/s00464-019-07160-8.
- [4] E. Rullier, Q. Denost, and V. Vendrely, "Low rectal cancer: classification and standardization of surgery," *Dis. Colon Rectum*, vol. 56, no. 5, pp. 560–567, 2013, doi: 10.1097/DCR.0b013e31827c4a8c.
- [5] S. Martin, H. Heneghan, and D. Winter, "Systematic review of outcomes after intersphincteric resection for low rectal cancer," *Br. J. Surg.*, vol. 99, no. 5, pp. 603–612, 2012, doi: 10.1002/bjs.8677.
- [6] C. Simillis, N. Lal, and S. Thoukididou, "Open Versus Laparoscopic Versus Robotic Versus Transanal Mesorectal Excision for Rectal Cancer: A Systematic Review and Network Meta-analysis," *Ann. Surg.*, vol. 270, no. 1, pp. 59–68, 2019, doi: 10.1097/SLA.0000000000003227.
- [7] S. Park, B. Park, and E. Park, "Outcomes of high versus low ligation of the inferior mesenteric artery with lymph node dissection for distal sigmoid colon or rectal cancer," *Surg. Today*, vol. 50, no. 6, pp. 560–568, 2020, doi: 10.1007/s00595-019-01942-2.
- [8] F. Kanso, J. Lefevre, and M. Svrcek, "Partial Mesorectal Excision for Rectal Adenocarcinoma: Morbidity and Oncological Outcome," *Clin. Colorectal Cancer*, vol. 15, no. 1, pp. 82–90.e1, 2016, doi: 10.1016/j.clcc.2015.07.008.
- [9] W. Zeng, M. Liu, and Z. Zhou, "A Distal Resection Margin of ≤ 1 mm and Rectal Cancer Recurrence After Sphincter-Preserving Surgery: The Role of a Positive Distal Margin in Rectal Cancer Surgery," *Dis. Colon Rectum*, vol. 60, no. 11, pp. 1175–1183, 2017, doi: 10.1097/DCR.0000000000000900.
- [10] C. Bertelsen, A. Neuenschwander, and J. Jansen, "Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study," *Lancet. Oncol.*, vol. 16, no. 2, pp. 161–168, 2015, doi: 10.1016/S1470-2045(14)71168-4.
- [11] C. Bertelsen, A. Neuenschwander, and J. Jansen, "5-year outcome after complete mesocolic excision for right-sided colon cancer: a population-based cohort study," *Lancet. Oncol.*, vol. 20, no. 11, pp. 1556–1565, 2019, doi: 10.1016/S1470-2045(19)30485-1.

Watch and Wait

- [1] A. Barina, A. De Paoli, and P. Delrio, "Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study," *Tech. Coloproctol.*, vol. 21, no. 8, pp. 633–640, 2017, doi: 10.1007/s10151-017-1665-1.
- [2] Y. Cui, X. Yang, and Z. Shi, "Radiomics analysis of multiparametric MRI for prediction of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer," *Eur. Radiol.*, vol. 29, no. 3, pp. 1211–1220, 2019, doi: 10.1007/s00330-018-5683-9.
- [3] G. Zhao, L. Deng, and D. Ye, "Efficacy and safety of wait and see strategy versus radical surgery and local excision for rectal cancer with cCR response after neoadjuvant chemoradiotherapy: a meta-analysis," *World J. Surg. Oncol.*, vol. 18, no. 1, p. 232, Aug. 2020, doi: 10.1186/s12957-020-02003-6.
- [4] F. Bettoni, C. Masotti, and B. Corrêa, "The Effects of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer-The Impact in Intratumoral Heterogeneity," *Front. Oncol.*, vol. 9, p. 974, 2019, doi: 10.3389/fonc.2019.00974.
- [5] B. Hupkens, and M. Maas, "ASO Author Reflections: Decision Timing for Organ Preservation in Rectal Cancer After Chemoradiation," *Ann. Surg. Oncol.*, vol. 25, no. Suppl 3, pp. 854–855, 2018, doi: 10.1245/s10434-018-7032-2.
- [6] B. Hupkens, M. Maas, and M. Martens, "Organ Preservation in Rectal Cancer After Chemoradiation: Should We Extend the Observation Period in Patients with a Clinical Near-Complete Response?," *Ann. Surg. Oncol.*, vol. 25, no. 1, pp. 197–203, 2018, doi: 10.1245/s10434-017-6213-8.
- [7] N. Battersby, M. Dattani, and S. Rao, "A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial," *Trials*, vol. 18, no. 1, p. 394, Aug. 2017, doi: 10.1186/s13063-017-2085-2.
- [8] A. Habr-Gama, G. São Julião, and B. Vailati, "Organ Preservation Among Patients With Clinically Node-Positive Rectal Cancer: Is It Really More Dangerous?," *Dis. Colon Rectum*, vol. 62, no. 6, pp. 675–683, 2019, doi: 10.1097/DCR.0000000000001337.
- [9] F. Quezada-Diaz, J. Smith, and R. Jimenez-Rodriguez, "Patient-Reported Bowel Function in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy After Neoadjuvant Therapy: A Case-Control Study," *Dis. Colon Rectum*, vol. 63, no. 7, pp. 897–902, 2020, doi: 10.1097/DCR.0000000000001646.
- [10] A. Rombouts, I. Al-Najami, and N. Abbott, "Can we Save the rectum by watchful waiting or TransAnal microsurgery following (chemo) Radiotherapy versus Total mesorectal excision for early RECTal Cancer (STAR-TREC study)?: protocol for a multicentre, randomised feasibility study," *BMJ Open*, vol. 7, no. 12, p. e019474, Dec. 2017, doi: 10.1136/bmjopen-2017-019474.

- [11] A. Habr-Gama, G. São Julião, and L. Fernandez, "Achieving a Complete Clinical Response After Neoadjuvant Chemoradiation That Does Not Require Surgical Resection: It May Take Longer Than You Think!," *Dis. Colon Rectum*, vol. 62, no. 7, pp. 802–808, 2019, doi: 10.1097/DCR.0000000000001338.
- [12] J. Smith, P. Strombom, and O. Chow, "Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy.," *JAMA Oncol.*, vol. 5, no. 4, p. e185896, Apr. 2019, doi: 10.1001/jamaoncol.2018.5896.
- [13] F. Rouleau-Fournier, and C. Brown, "Can less be more? Organ preservation strategies in the management of rectal cancer.," *Curr. Oncol.*, vol. 26, no. Suppl 1, pp. S16–S23, 2019, doi: 10.3747/co.26.5841.
- [14] M. van der Valk, D. Hilling, and E. Bastiaannet, "Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.," *Lancet (London, England)*, vol. 391, no. 10139, pp. 2537–2545, Jun. 2018, doi: 10.1016/S0140-6736(18)31078-X.
- [15] L. Bernier, S. Balyasnikova, and D. Tait, "Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer.," *Curr. Colorectal Cancer Rep.*, vol. 14, no. 2, pp. 37–55, 2018, doi: 10.1007/s11888-018-0398-5.
- [16] M. Strode, R. Shah, and P. Boland, "Nonoperative management after neoadjuvant therapy for rectal cancer: A single institution experience over 5 years.," *Surg. Oncol.*, vol. 28, pp. 116–120, 2019, doi: 10.1016/j.suronc.2018.11.012.
- [17] L. Sposato, Y. Lam, and C. Karapetis, "Observation of "complete clinical response" in rectal cancer after neoadjuvant chemoradiation: The Flinders experience.," *Asia. Pac. J. Clin. Oncol.*, vol. 14, no. 6, pp. 439–445, 2018, doi: 10.1111/ajco.12993.
- [18] M. Maas, D. Lambregts, and P. Nelemans, "Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI: Selection for Organ-Saving Treatment.," *Ann. Surg. Oncol.*, vol. 22, no. 12, pp. 3873–3880, 2015, doi: 10.1245/s10434-015-4687-9.
- [19] R. Smith, R. Fry, and N. Mahmoud, "Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision.," *Int. J. Colorectal Dis.*, vol. 30, no. 6, pp. 769–774, 2015, doi: 10.1007/s00384-015-2165-2.